 |
|
Non-alcoholic fatty liver disease: Definition and subtypes
Seul Ki Han, Soon Koo Baik, Moon Young Kim
Clin Mol Hepatol. 2023;29(suppl):S5-S16. Published online 2022 Dec 28 DOI: https://doi.org/10.3350/cmh.2022.0424
|
|
Citations to this article as recorded by
 The interplay between chronic hepatitis B and diabetes mellitus: A narrative and concise review
Shang‐Chin Huang, Jia‐Horng Kao
The Kaohsiung Journal of Medical Sciences.2024; 40(1): 6. CrossRef LncRNA Gm28382 promotes lipogenesis by interacting with miR-326-3p to regulate ChREBP signaling pathway in NAFLD
Sen Yang, Yang Zhang, Yan Zhang, Lianhong Yin, Xu Han, Xuerong Zhao, Ning Wang, Lina Xu
International Immunopharmacology.2024; 127: 111444. CrossRef Role of Perturbated Hemostasis in MASLD and Its Correlation with Adipokines
Salvatore Pezzino, Tonia Luca, Mariacarla Castorina, Stefano Puleo, Saverio Latteri, Sergio Castorina
Life.2024; 14(1): 93. CrossRef From Nonalcoholic Fatty Liver Disease to Metabolic Dysfunction-Associated Steatotic Liver Disease: Out with the Old, in with the New
Iyiad Alabdul Razzak, Mazen Noureddin, Hirsh Trivedi
Journal of Clinical Medicine.2024; 13(3): 880. CrossRef Research Progress of MIF in Nonalcoholic Fatty Liver Disease
·阿不力提浦 阿依古扎丽
Advances in Clinical Medicine.2024; 14(02): 2483. CrossRef Hepatic Stellate Cell‐Targeting Micelle Nanomedicine for Early Diagnosis and Treatment of Liver Fibrosis
Lei Wang, Jieying Zhou, Jian Wang, Xiaotang Wang, Haijuan Dong, Lingzhi Zhao, Junchen Wu, Juanjuan Peng
Advanced Healthcare Materials.2024;[Epub] CrossRef Not Only Metabolic Complications of Childhood Obesity
Sebastian Ciężki, Emilia Odyjewska, Artur Bossowski, Barbara Głowińska-Olszewska
Nutrients.2024; 16(4): 539. CrossRef Effect of Statins for Primary Prevention of Cardiovascular Disease According to the Fatty Liver Index
Joonsang Yoo, Jimin Jeon, Minyoul Baik, Jinkwon Kim
Journal of Epidemiology and Global Health.2024;[Epub] CrossRef Ferroptosis in Liver Disease: Natural Active Compounds and Therapeutic Implications
Zhili Wu, Yanru Zhu, Wenchao Liu, Balamuralikrishnan Balasubramanian, Xiao Xu, Junhu Yao, Xinjian Lei
Antioxidants.2024; 13(3): 352. CrossRef Lipidomic Analysis of Liver and Adipose Tissue in a High-Fat Diet-Induced Non-Alcoholic Fatty Liver Disease Mice Model Reveals Alterations in Lipid Metabolism by Weight Loss and Aerobic Exercise
Thomai Mouskeftara, Olga Deda, Grigorios Papadopoulos, Antonios Chatzigeorgiou, Helen Gika
Molecules.2024; 29(7): 1494. CrossRef Puerarin Induces Macrophage M2 Polarization to Exert Antinonalcoholic Steatohepatitis Pharmacological Activity via the Activation of Autophagy
Xiaoxue Fang, Xintian Lan, Ming Zhu, Min He, Mengmeng Sun, Yiming Cao, Difu Zhu, Dean Guo, Haoming Luo
Journal of Agricultural and Food Chemistry.2024; 72(13): 7187. CrossRef Metabolic-Associated Steatotic Liver Disease (MASLD): A New Term for a More Appropriate Therapy in Pediatrics?
Antonella Mosca, Andrea Pietrobattista, Giuseppe Maggiore
Pediatric Reports.2024; 16(2): 288. CrossRef Deciphering the molecular pathways of saroglitazar: A dual PPAR α/γ agonist for managing metabolic NAFLD
Devaraj Ezhilarasan
Metabolism.2024; 155: 155912. CrossRef Non-alcoholic fatty liver disease: new additional non-invasive diagnostic markers and risks of comorbid diseases
Kh.A. Moskva, O.P. Kikhtyak, M.L. Farmaha, Ya.L. Leshchuk, M.Yu. Horecha
INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine).2024; 20(2): 99. CrossRef SGLT2i impact on HCC incidence in patients with fatty liver disease and diabetes: a nation-wide cohort study in South Korea
Hyo Jung Cho, Eunyoung Lee, Soon Sun Kim, Jae Youn Cheong
Scientific Reports.2024;[Epub] CrossRef Roflumilast ameliorates GAN diet-induced non-alcoholic fatty liver disease by reducing hepatic steatosis and fibrosis in ob/ob mice
Bin Wang, Xiaochan Zhu, Siting Yu, Huan Xue, Lijiao Deng, Yushan Zhang, Yi Zhang, Yunfeng Liu
Biochemical and Biophysical Research Communications.2024; 722: 150170. CrossRef Small intestinal bacterial overgrowth in obese patients with biopsy-confirmed metabolic dysfunction-associated steatotic liver disease: a cross-sectional study
Nicolás Ortiz-López, Ana María Madrid, Larissa Aleman, Alejandra Zazueta, Gladys Smok, Lucía Valenzuela-Pérez, Jaime Poniachik, Caroll J. Beltrán
Frontiers in Medicine.2024;[Epub] CrossRef The effect of probiotic consumption on lipid profile, glycemic index, inflammatory markers, and liver function in NAFLD patients: A systematic review and meta-analysis of randomized controlled trials
Sadegh Mozaffari, Mahdeyeh Aliari, Solaleh Emamgholipour, Hossein Hosseini, Pedram Rezaei Amirkiasar, Mina Zare, Niki Katsiki, Ghodratollah Panahi, Amirhossein Sahebkar
Journal of Diabetes and its Complications.2024; 38(8): 108780. CrossRef SPRED2 Is a Novel Regulator of Autophagy in Hepatocellular Carcinoma Cells and Normal Hepatocytes
Tianyi Wang, Tong Gao, Masayoshi Fujisawa, Toshiaki Ohara, Masakiyo Sakaguchi, Teizo Yoshimura, Akihiro Matsukawa
International Journal of Molecular Sciences.2024; 25(11): 6269. CrossRef The independent and joint associations of vitamin B12 and methylmalonic acid on the risk of mortality in individuals with metabolic dysfunction-associated steatotic liver disease
Peng Wang, Jing Yu, Yaxuan Zhao, Rukiya Simayi, Dan Shi
European Journal of Nutrition.2024;[Epub] CrossRef Lycopene: A Potent Antioxidant with Multiple Health Benefits
Mercy Omoye Shafe, Nontobeko Myllet Gumede, Trevor Tapiwa Nyakudya, Eliton Chivandi, Toshikazu Suzuki
Journal of Nutrition and Metabolism.2024;[Epub] CrossRef Association between hemoglobin and non-alcoholic fatty liver disease (NAFLD) in United States adults: Results from NHANES 2017–2020
Kang Yao, Zheng Chen, Wei Zhou, Zhihua Liu, Wei Cui
Preventive Medicine Reports.2024; 44: 102798. CrossRef Effects of a Two-Year Lifestyle Intervention on Intrahepatic Fat Reduction and Renal Health: Mitigation of Inflammation and Oxidative Stress, a Randomized Trial
Maria Magdalena Quetglas-Llabrés, Margalida Monserrat-Mesquida, Cristina Bouzas, Silvia García, David Mateos, Miguel Casares, Cristina Gómez, Lucía Ugarriza, Josep A. Tur, Antoni Sureda
Antioxidants.2024; 13(7): 754. CrossRef The causal relationship between non-alcoholic fatty liver disease, hypertension, and cardiovascular diseases: implications for future research
Toshiki Maeda
Hypertension Research.2024;[Epub] CrossRef Role of Nonalcoholic Fatty Liver Disease in Periodontitis: A Bidirectional Relationship
Hardika S Vegda, Bhavin Patel, Gaurav A Girdhar, Mohd. Shabankhan H Pathan, Rahnuma Ahmad, Mainul Haque, Susmita Sinha, Santosh Kumar
Cureus.2024;[Epub] CrossRef Lean vs. obese phenotypes of nonalcoholic fatty liver disease: similar or different?
Ho Soo Chun, Minjong Lee
Clinical and Molecular Hepatology.2023; 29(2): 377. CrossRef The Janus-Faced Role of Lipid Droplets in Aging: Insights from the Cellular Perspective
Nikolaus Bresgen, Melanie Kovacs, Angelika Lahnsteiner, Thomas Klaus Felder, Mark Rinnerthaler
Biomolecules.2023; 13(6): 912. CrossRef Protective effects of statins on the incidence of NAFLD–related decompensated cirrhosis in T2DM
Szu‐Yuan Wu, Wan‐Ming Chen, Ming‐Feng Chiang, Hung‐Chieh Lo, Ming‐Shun Wu, Ming‐Che Lee, Ruey‐Shyang Soong
Liver International.2023; 43(10): 2232. CrossRef Editorial: Will MRI‐PDFF become the new standard for steatosis assessment in NAFLD?
Angeliki Pappa, Tobias Wenzl
Alimentary Pharmacology & Therapeutics.2023; 58(3): 364. CrossRef Letter regarding “Non-alcoholic fatty liver disease: Definition and subtypes”
Seogsong Jeong, Yohwan Lim, Su Kyoung Lee, Hyun Wook Han
Clinical and Molecular Hepatology.2023; 29(3): 810. CrossRef Non-Alcoholic Fatty Liver Disease and Echocardiographic Parameters of Left Ventricular Diastolic Function: A Systematic Review and Meta-Analysis
Athina Goliopoulou, Panagiotis Theofilis, Evangelos Oikonomou, Artemis Anastasiou, Panteleimon Pantelidis, Maria Ioanna Gounaridi, Georgios E. Zakynthinos, Ourania Katsarou, Eva Kassi, Vaia Lambadiari, Dimitris Tousoulis, Manolis Vavuranakis, Gerasimos Si
International Journal of Molecular Sciences.2023; 24(18): 14292. CrossRef Critical appraisal of metabolic dysfunction-associated steatotic liver disease: Implication of Janus-faced modernity
Gi-Ae Kim, Joon Ho Moon, Won Kim
Clinical and Molecular Hepatology.2023; 29(4): 831. CrossRef Association between Impaired Ketogenesis and Metabolic-Associated Fatty Liver Disease
Jaehyun Bae, Byung-Wan Lee
Biomolecules.2023; 13(10): 1506. CrossRef The evolving role of lenvatinib at the new era of first-line hepatocellular carcinoma treatment
Landon L. Chan, Stephen L. Chan
Clinical and Molecular Hepatology.2023; 29(4): 909. CrossRef Comparison of the efficacy and safety of hypoglycemic treatments in patients with non-alcoholic fatty liver disease and type-2 diabetes: a systematic review and Bayesian network analysis
Nuojin Guo, Hekai Shi, Hao Zhang, Hua Wang
European Journal of Clinical Pharmacology.2023; 79(11): 1465. CrossRef Clinical Classification of Obesity and Implications for Metabolic Dysfunction-Associated Fatty Liver Disease and Treatment
Yuping Ding, Quanjun Deng, Mei Yang, Haiyan Niu, Zuoyu Wang, Shihai Xia
Diabetes, Metabolic Syndrome and Obesity.2023; Volume 16: 3303. CrossRef
|